FDA — authorised 17 February 2022
- Marketing authorisation holder: AGIOS PHARMACEUTICALS INC
- Status: approved
🇺🇸 Pyrukynd in United States
FDA authorised Pyrukynd on 17 February 2022
Marketing authorisations
FDA — authorised 17 February 2022
- Application: NDA216196
- Marketing authorisation holder: AGIOS PHARMS INC
- Local brand name: PYRUKYND
- Indication: TABLET — ORAL
- Status: approved
Pyrukynd in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Pyrukynd approved in United States?
Yes. FDA authorised it on 17 February 2022; FDA authorised it on 17 February 2022.
Who is the marketing authorisation holder for Pyrukynd in United States?
AGIOS PHARMACEUTICALS INC holds the US marketing authorisation.